Curevac announces financial results for the second quarter and first half of 2023 and provides business update

Initiated phase 2 study in covid-19 with monovalent and bivalent, modified mrna vaccine candidates; continued execution on infectious disease development program in collaboration with gsk initiated phase 1 study of cancer vaccine candidate, cvgbm, for surgically resected glioblastoma; recruitment of second dose cohort well on track broadened position in patent litigations by expanding the scope and asserting new intellectual property rights in germany and the u.s. public hearing held before the regional court dÜsseldorf as part of german patent litigation against pfizer/biontech cash and cash equivalents position of €537.9 million as of june 30, 2023 tÜbingen, germany and boston, ma / accesswire / august 17, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced financial results for the second quarter and first half of 2023 and provided a business update.
CVAC Ratings Summary
CVAC Quant Ranking